Skip to main content

Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9.

Jung K, Klotzek S, Stephan C, Mannello F, Lein M

Publication: Clin Chem (2008) • Vol 54 • Page 772-3PMID: 18375496View on PubMed

Purpose

The purpose of this paper was to determine if blood matrix metalloproteinase (MMP) levels differ as a result of anticoagulant type.

Conclusion

MMP-1, -8, and -9 differed significantly among differentially treated serum and plasma specimens, while MMP-2, -3, and -7 levels were comparable among serum and plasma-citrate and plasma-heparin specimens.

Studies (1)

Purpose

The purpose of this study was to determine if blood matrix metalloproteinase (MMP) levels differ as a result of anticoagulant type or the presence of a coagulant accelerator.

Summary of Findings

In general, MMP concentrations were higher in serum than in plasma specimens. In comparison to additive-free serum, serum treated with a coagulant accelerator (kaolin-coated granules) displayed significantly higher MMP-1, -8, and -9 levels. Conversely, levels of MMP-2, -3, and -7 were comparable among serum with and without additives as well as sodium citrate or lithium heparin treated plasma specimens.

  • Biospecimens

    FluidPlasma
    FluidSerum
    FluidBlood
  • Preservation Types

    Frozen
  • Diagnoses

    Normal
  • Platforms

    ProteinAutomated electrophoresis/Bioanalyzer
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionAnticoagulant
    Lithium heparin
    None
    Potassium EDTA
    Sodium citrate
    Biospecimen Aliquots and ComponentsBlood and blood products
    Plasma
    Serum